Literature DB >> 18384505

The reactive oxygen-driven tumor: relevance to melanoma.

Levi Fried1, Jack L Arbiser.   

Abstract

In melanoma, at least four major signaling abnormalities have been described. They include beta-catenin deregulation (mutation/mislocalization), p16 loss, MAP kinase activation, and Akt activation. In this review, we discuss the role of the fourth pathway, known as the reactive oxygen driven tumor. The role of reactive oxygen in tumorigenesis is likely to relate to virtually all forms of cancer, and lends itself to specific therapies. These include blockade of reactive oxygen, resulting in decreased activation of NF-kappaB, which should sensitize tumors to chemotherapy and radiation. The phenotype of the reactive oxygen driven tumor can be monitored using available markers already in use in most hospital laboratories.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18384505     DOI: 10.1111/j.1755-148X.2008.00451.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  44 in total

1.  Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice.

Authors:  Vijayalakshmi Nandakumar; Mudit Vaid; Trygve O Tollefsbol; Santosh K Katiyar
Journal:  Carcinogenesis       Date:  2010-12-24       Impact factor: 4.944

Review 2.  Application of angiogenesis to clinical dermatology.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Adv Dermatol       Date:  2008

3.  RGS-GAIP-interacting protein controls breast cancer progression.

Authors:  Ling Wang; Julie S Lau; Chitta Ranjan Patra; Ying Cao; Santanu Bhattacharya; Shamit Dutta; Debashis Nandy; Enfeng Wang; Chamila N Rupasinghe; Pawan Vohra; Mark R Spaller; Debabrata Mukhopadhyay
Journal:  Mol Cancer Res       Date:  2010-10-27       Impact factor: 5.852

4.  A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo.

Authors:  Pamela B Cassidy; Tong Liu; Scott R Florell; Matthew Honeggar; Sancy A Leachman; Kenneth M Boucher; Douglas Grossman
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-05

5.  MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.

Authors:  I Made Winarsa Ruma; Endy Widya Putranto; Eisaku Kondo; Hitoshi Murata; Masami Watanabe; Peng Huang; Rie Kinoshita; Junichiro Futami; Yusuke Inoue; Akira Yamauchi; I Wayan Sumardika; Chen Youyi; Ken-Ichi Yamamoto; Yasutomo Nasu; Masahiro Nishibori; Toshihiko Hibino; Masakiyo Sakaguchi
Journal:  Clin Exp Metastasis       Date:  2016-05-05       Impact factor: 5.150

6.  Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG).

Authors:  Minakshi Nihal; Craig T Roelke; Gary S Wood
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

7.  BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Authors:  Supriya Gaitonde; Surya K De; Marianna Tcherpakov; Antimone Dewing; Hongbin Yuan; Megan Riel-Mehan; Stan Krajewski; Gavin Robertson; Maurizio Pellecchia; Ze'ev Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

Review 8.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

9.  GLO1 overexpression in human malignant melanoma.

Authors:  Warner B Bair; Christopher M Cabello; Koji Uchida; Alexandra S Bause; Georg T Wondrak
Journal:  Melanoma Res       Date:  2010-04       Impact factor: 3.599

10.  Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1.

Authors:  Christopher M Cabello; Warner B Bair; Alexandra S Bause; Georg T Wondrak
Journal:  Biochem Pharmacol       Date:  2009-04-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.